Alnylam Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Yvonne L. Greenstreet
- Full Time Employees
- 2,500
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 675 West Kendall Street Cambridge MA United States of America 02142
- IPO Date
- Jun 1, 2004
- CIK
- 0001178670
- Website
- alnylam.com
- Similar Companies
- Business
- Alnylam Pharmaceuticals, Inc. (ALNY) develops and commercializes RNA interference (RNAi) therapeutics targeting genetically defined diseases; core products include ONPATTRO (patisiran) for hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy, AMVUTTRA (vutrisiran) for ATTR amyloidosis with polyneuropathy or cardiomyopathy, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1; the company also advances partnered programs such as Leqvio (inclisiran) for hypercholesterolemia marketed by Novartis. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam operates globally with key facilities in the US, Europe (including France, Italy, Netherlands, Sweden, Switzerland, and the UK), and Japan. The company maintains strategic collaborations with Roche on zilebesiran for hypertension, Regeneron for CNS diseases, Sanofi on fitusiran for hemophilia, and others including Novartis and Agios Pharmaceuticals. Recent developments encompass expansion of AMVUTTRA into ATTR cardiomyopathy with strong launch uptake and upgraded 2025 revenue guidance, initiation of a Phase 1 trial for ALN-4324 targeting GRB14 for type 2 diabetes, and Agios' IND clearance for AG-236 (ALN-TMP) in polycythemia vera; Alnylam joined the Alliance for Genomic Discovery in 2025 to leverage datasets for gene-silencing medicines and extended its partnership with Medison Pharma into LATAM and APAC markets. Pipeline advancements feature nucresiran for ATTR amyloidosis, mivelsiran for Alzheimer's disease and cerebral amyloid angiopathy, and positive Phase 3 data for zilebesiran. These efforts support Alnylam's transition to profitability with 2024 net product revenues exceeding $1.3 billion across rare and cardiometabolic indications.
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Continuing Securities Fraud Investigation
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options
ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law
ALNYLAM INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm
Securities Fraud Investigation into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged to Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Continuing Securities Fraud Investigation
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law
ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law
ALNYLAM PHARMACEUTICALS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
ALNY Stock Tanks 28% as Q2 Earnings Miss Estimates, '26 Sales View Cut
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2026 Earnings Call Transcript
Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks
Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Alnylam Pharmaceuticals (ALNY) Misses Q2 Earnings and Revenue Estimates